Published in Oncologist on March 31, 2016
Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML. Biomed Res Int (2016) 0.75
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Chronic myeloid leukemia. N Engl J Med (1999) 7.11
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 5.20
Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst (1960) 4.15
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol (2008) 3.85
Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem (2002) 3.72
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res (2006) 3.47
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell (2014) 3.08
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A (1987) 3.03
Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 2.93
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol (2012) 2.90
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood (2009) 2.87
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol (2009) 2.56
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood (2012) 2.46
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia (2015) 2.37
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 2.36
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des (2010) 2.19
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood (2013) 2.18
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature (2015) 1.99
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood (2007) 1.92
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica (2007) 1.76
Harmonization of molecular monitoring of CML therapy in Europe. Leukemia (2009) 1.76
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia (2010) 1.58
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem (2013) 1.58
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood (2012) 1.47
Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol (2009) 1.35
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res (2005) 1.35
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood (2010) 1.26
Treatment of chronic myeloid leukemia in blast crisis. Haematologica (2008) 1.25
Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res (2013) 1.19
High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood (2007) 1.19
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood (1995) 1.18
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res (2013) 1.16
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13
Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia (2002) 1.08
Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. Eur J Cancer (2013) 1.08
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood (1995) 1.07
Molecular monitoring of chronic myeloid leukemia. Semin Hematol (2003) 1.03
Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant (1996) 1.02
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol (2006) 1.00
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol (2014) 0.96
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood (1999) 0.96
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk (2010) 0.96
BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol (2012) 0.95
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res (2003) 0.93
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol (2007) 0.92
Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol (2009) 0.92
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol (2013) 0.91
Dasatinib. Recent Results Cancer Res (2014) 0.91
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. Pharmacogenomics (2012) 0.90
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol (2014) 0.90
Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol. Leuk Res (2005) 0.89
Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther (2008) 0.88
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol (2000) 0.87
Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol (2010) 0.87
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol (2015) 0.85
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol (2009) 0.84
Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol (2015) 0.83
Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res (2014) 0.82
Genetic mechanisms of chronic myeloid leukemia blastic transformation. Curr Hematol Malig Rep (2012) 0.82
Response-related predictors of survival in CML. Ann Hematol (2015) 0.82
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica (2015) 0.81
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood (2015) 0.80
Nilotinib. Recent Results Cancer Res (2014) 0.80
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica (2009) 0.80
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? Oncologist (2011) 0.79
Bosutinib: a novel second-generation tyrosine kinase inhibitor. Recent Results Cancer Res (2014) 0.79
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation. J Hematol Oncol (2015) 0.79
Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2014) 0.78
The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica (2005) 0.77
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay. Leukemia (1999) 0.76